Drug intelligence / Profile preview

DW1029M + losartan

Development stage: Unknown
Lead developer: Dong-A ST
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

DW1029M + losartan is a fixed-dose combination therapy being developed by Dong-A ST for the treatment of diabetic nephropathy. DW1029M is a botanical drug candidate composed of extracts from *Morus alba* (mulberry) and *Stevia rebaudiana* leaves, which has demonstrated glucose-lowering and renoprotective effects in preclinical models. Losartan is a standard-of-care angiotensin II receptor blocker (ARB) used to manage hypertension and protect renal function in diabetic patients. The combination aims to provide synergistic effects in reducing albuminuria and slowing the progression of kidney damage in patients with type 2 diabetes by combining the metabolic and anti-inflammatory benefits of the botanical extract with the hemodynamic benefits of the ARB.

Other names: DW-1029M + losartanDW1029M and losartanDW-1029M and losartanDW 1029M and losartanMorus alba and Stevia rebaudiana extract + losartan

Targets

Fe2+ (Ferrous iron)AKR1B1 (Aldose Reductase)AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on DW1029M + losartan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DW1029M + losartan.

Explore the full profile